Ocular Mucous Membrane Pemphigoid Presenting as Recurrent Pterygium.

Autor:	Tallapelly HG; Shantilal Shanghvi Cornea Institute, L V Prasad Eye Institute, Vijayawada, India.; Academy for Eye Care Education, L V Prasad Eye Institute, Hyderabad, India., Shanbhag SS; Academy for Eye Care Education, L V Prasad Eye Institute, Hyderabad, India., Basu S; Shantilal Shanghvi Cornea Institute, L V Prasad Eye Institute, Hyderabad, India.; Centre for Ocular Regeneration (CORE), L V Prasad Eye Institute, Hyderabad, India; and., Kate A; Shantilal Shanghvi Cornea Institute, L V Prasad Eye Institute, Vijayawada, India.
Jazyk:	angličtina
Zdroj:	Cornea [Cornea] 2024 Aug 29. Date of Electronic Publication: 2024 Aug 29.
DOI:	10.1097/ICO.0000000000003683
Abstrakt:	Purpose: The aim of this series was to report recurrent pterygium as a presenting feature of ocular mucous membrane pemphigoid (oMMP). Methods: A retrospective review was performed, and patients with biopsy positive oMMP who presented with recurrent pterygia were included. Data on the demographic profile, clinical characteristics, and details of the surgical intervention were collected. Results: A total of 5 patients with recurrent pterygium were included. All the patients were men. The median age was 63 years. History of pterygium surgery was present in 8/10 eyes (80%), of which 6 eyes (60%) developed a recurrent pterygium. A symblepharon was present in 4/6 eyes (67%). Forniceal shortening was present in 10/10 (100%) eyes. All eyes were subjected to a conjunctival biopsy for direct immunofluorescence, of which 9 eyes (90%) had positive results consistent with oMMP. Systemic immunomodulatory therapy (IMT) with either methotrexate or azathioprine was initiated in all 5 patients. Conclusions: Recurrent pterygium can be a presenting feature of oMMP. The presence of symblepharon formation or forniceal shortening, especially in the fellow eye, warrants a conjunctival biopsy and prompt initiation of IMT to prevent disease progression. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu